Questions regarding frontline therapy of acute myeloid leukemia-Reference-Cited by-同舟云学术

Questions regarding frontline therapy of acute myeloid leukemia

Published:2010-07-09 Issue:21 Volume:116 Page:4896-4901
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop,O'Brien Susan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25281/fullpdf

Reference24 articles.

1. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group;Rowe;Cancer.,2010

2. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N Engl J Med.,1994

3. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995);Cassileth;Leuk Lymphoma.,2005

4. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia;AML Collaborative Group. Br J Haematol.,1998

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparity in hematological malignancies: From patients to health care professionals;Blood Reviews;2024-05

2. Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies;European Journal of Pharmaceutical Sciences;2024-02

3. Advances in the Treatment of Senile Acute Myeloid Leukemia;Advances in Clinical Medicine;2023

4. A multi‐institutional comparison of mitoxantrone, etoposide, and cytarabine vs high‐dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia;American Journal of Hematology;2020-05-08

5. Inhibition of UBE2L6 attenuates ISGylation and impedes ATRA‐induced differentiation of leukemic cells;Molecular Oncology;2020-05